Evidence map›Paper›PMID 38975756›Full record

ArticlemBio2024

Sadie R Schaus, Gabriel Vasconcelos Pereira, Ana S Luis, Emily Madlambayan, Nicolas Terrapon, Matthew P Ostrowski, Chunsheng Jin, Bernard Henrissat, Gunnar C Hansson, Eric C Martens

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Gut microbes · 2026
    Article
  8. Gut microbes · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Update of
    2024
5 · Who and what money

Authors and funding

10 authors.

Sadie R SchausDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-2037-5913
Gabriel Vasconcelos PereiraDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-7937-474X
Ana S LuisDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Emily MadlambayanDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Nicolas TerraponCentre National de la Recherche Scientifique, Aix-Marseille University, Marseille, France.
Matthew P OstrowskiDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Chunsheng JinProteomics Core Facility at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Bernard HenrissatDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
Gunnar C HanssonDepartment of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.
Eric C MartensDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-6681-2990

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MERCHANT, JUANITA L. · 1986 to 2021
$22.5M
Metabolomics CoreP01HL149633 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TEWARI, MUNEESH · 2020 to 2024
$11.1M
Low dietary fiber and gut microbiota-induced mucus layer erosion as IBD triggersR01DK118024 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRACE Y. CHEN, Eric C Martens · 2018 to 2026
$4.9M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Unraveling the enzymatic pathway of gut bacterial mucus degradation to treat inflammationR01DK125445 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOROPATKIN, NICOLE M, MARTENS, ERIC C · 2020 to 2023
$2.2M
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL149633HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK118024HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK125445NCATS NIH HHS UL1 TR002240NHLBI NIH HHS P01 HL149633NIDDK NIH HHS P30 DK034933NIDDK NIH HHS R01 DK118024NIDDK NIH HHS R01 DK125445NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Symbiotic interactions between humans and our communities of resident gut microbes (microbiota) play many roles in health and disease. Some gut bacteria utilize mucus as a nutrient source and can under certain conditions damage the protective barrier it forms, increasing disease susceptibility. We investigated how

Indexed as

Bacteroides thetaiotaomicronGastrointestinal MicrobiomeMucinsOligosaccharidesRuminococcusGlycoproteinsHumansSymbiosisGlycoproteinsMucinsOligosaccharidesglycoproteininflammatory bowel diseasemicrobiotamucusRuminococcus torques

Identifiers

PMID38975756
PMCPMC11323728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.